Novartis to Launch Direct-to-Patient Platform for Cosentyx in U.S.
PositiveHealth

Novartis is set to launch a direct-to-patient platform for its drug Cosentyx in the U.S., marking a significant step in making medications more accessible. This initiative comes as part of a broader trend among pharmaceutical companies to reduce prices ahead of the Trump administration's deadline, which aims to enhance affordability for patients. By streamlining the process, Novartis not only addresses patient needs but also positions itself as a leader in the evolving healthcare landscape.
— Curated by the World Pulse Now AI Editorial System